Oncogenic KRAS, Mucin 4, and Activin A‐Mediated Fibroblast Activation Cooperate for PanIN Initiation
Advanced Science · 2023-12 · 10 (36)
DOI: 10.1002/advs.202301240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 14.11.2023. Verfasst von Chun-Mei Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Research Center, Academia Sinica, Taipei, 11529, Taiwan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Carcinoma in Situ. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academia Sinica, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Over 90% of patients with pancreatic ductal adenocarcinoma (PDAC) have oncogenic KRAS mutations. Nevertheless, mutated KRAS alone is insufficient to initiate pancreatic intraepithelial neoplasia (PanIN), the precursor of PDAC. The identities of the other factors/events required to drive PanIN formation remain elusive. Here, optic‐clear 3D histology is used to analyze entire pancreases of 2‐week‐old Pdx1 ‐ Cre ; LSL ‐ Kras G12D/+ (KC) mice to detect the earliest emergence of PanIN and observed that the occurrence is independent of physical location. Instead, it is found that the earliest PanINs overexpress Muc4 and associate with αSMA + fibroblasts in both transgenic mice and human specimens. Mechanistically, Kras G12D/+ pancreatic cells upregulate Muc4 through genetic alterations to increase proliferation and fibroblast recruitments via Activin A secretion and consequently enhance cell transformation for PanIN formation. Inhibition of Activin A signaling using Follistatin (FST) diminishes early PanIN‐associated fibroblast recruitment, effectively curtailing PanIN initiation and growth in KC mice. These findings emphasize the vital role of interactions between oncogenic Kras G12D/+ ‐driven genetic alterations and induced microenvironmental changes in PanIN initiation, suggesting potential avenues for early PDAC diagnostic and management approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
- Biomedical Translation Research Center, Academia Sinica, Taipei, 11529, Taiwan.
- Department of Pathology, National Taiwan University Hospital, Taipei, 10041, Taiwan.
- Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, 10041, Taiwan.
- Department of Medical Science, National Tsing Hua University, Hsinchu, 30013, Taiwan.
- Department of Pathology, National Taiwan University Hospital-Hsinchu Branch, Hsinchu, 30331, Taiwan.
ORCID-Profile: Chun-Mei Hu, Wen-Hwa Lee
Förderung
- Academia Sinica
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Hu, C. M., Huang, C. C., Hsu, M. F., Chien, H. J., Wu, P. J., Chen, Y. I., Jeng, Y. M., Tang, S. C., Chung, M. H., Shen, C. N., Chang, M. C., Chang, Y. T., Tien, Y. W., & Lee, W. H. (2023). Oncogenic KRAS, Mucin 4, and Activin A‐Mediated Fibroblast Activation Cooperate for PanIN Initiation. Advanced Science, 10(36). https://doi.org/10.1002/advs.202301240
Vancouver
Hu CM, Huang CC, Hsu MF, Chien HJ, Wu PJ, Chen YI, et al. Oncogenic KRAS, Mucin 4, and Activin A‐Mediated Fibroblast Activation Cooperate for PanIN Initiation. Advanced Science. 2023;10(36). doi:10.1002/advs.202301240
BibTeX
@article{Hu2023,
author = {Hu, Chun-Mei and Huang, Chien-Chang and Hsu, Min-Fen and Chien, Hung-Jen and Wu, Pei-Jung and Chen, Yi-Ing and Jeng, Yung-Ming and Tang, Shiue-Cheng and Chung, Mei-Hsin and Shen, Chia-Ning and Chang, Ming-Chu and Chang, Yu-Ting and Tien, Yu-Wen and Lee, Wen-Hwa},
title = {Oncogenic KRAS, Mucin 4, and Activin A‐Mediated Fibroblast Activation Cooperate for PanIN Initiation},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {36},
doi = {10.1002/advs.202301240}
}
EUVIMED